SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol ...
The National Pharmaceutical Pricing Authority (NPPA) has sought manufacturers and marketing companies of iohexol injection 300 mg iodine per ML, a diagnostic agent, to submit price and market data on ...
The National Pharmaceutical Pricing Authority (NPPA) has issued the revised ceiling price of iohexol injection 300 mg iodine per ML, a diagnostic agent, with a 14.8 percent reduction from the existing ...
BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced Thursday that the U.S. Food and Drug Administration has approved its iohexol injection (300 mg Iodine/mL), the first generic ...
BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal” or the "Company”) (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved ...
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results